SPDR S&P Biotech ETF Newsroom

Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"

Benzinga20minutes ago

Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.

Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.

wallstreetcnNov 15 23:02

What kind of company is Natera, the largest hold positions of Drew Miller?

Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.

wallstreetcnNov 15 21:25

Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.

① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.

cls.cnNov 15 10:14

SPDR S&P Biotech ETF Options Spot-On: On November 14th, 160.61K Contracts Were Traded, With 954.71K Open Interest

On November 14th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 160.61K options for the day, of which put options accounted for 65.41% of the total

Futu NewsNov 15 05:30

Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades

Seeking AlphaNov 15 05:24

Cracking The Code: Understanding Analyst Reviews For Incyte

BenzingaNov 15 04:00

Gilead, Vertex Initiated as New Big Biotech Buys at Citi

Seeking AlphaNov 15 03:26

Incyte Analyst Ratings

BenzingaNov 15 01:05 · Ratings

Amgen's Options Frenzy: What You Need to Know

BenzingaNov 15 00:15

InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia

BenzingaNov 14 22:04

Gilead Sciences Analyst Ratings

BenzingaNov 14 20:58 · Ratings

Vertex Pharmaceuticals Analyst Ratings

BenzingaNov 14 20:51 · Ratings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaNov 14 05:05

Natera Analysts Increase Their Forecasts Following Upbeat Results

BenzingaNov 14 02:38

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaNov 14 01:35

Live On CNBC, Joe Terranova Announces Sold Amgen

BenzingaNov 14 01:25

Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday

BenzingaNov 13 23:19

4 Stocks to Watch on Wednesday: AMGN, CSCO and More

Seeking AlphaNov 13 22:12

Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday

BenzingaNov 13 20:45